AliveX Biotech Launches Multi-Million-Yuan Funding Initiative to Empower Clinical Research and Innovation
AliveX Biotech
Precision Medicine Solution Provider
Since its establishment, AliveX Biotech has been committed to promoting innovation and development in the field of life sciences. We focus on the production of high-quality multi-omics experimental data and efficiently explore disease and pharmacological mechanisms through a globally leading AI bio-computing platform, empowering translational medicine. Meanwhile, AliveX Biotech also benefits from the guidance of an international and interdisciplinary team of academician professors, providing every partner with professional, scientific, and rigorous precision medicine products and research solutions.
Today, we are honored to introduce to our partners the multi-million funding initiative led by AliveX Biotech. This initiative aims to provide innovative and cutting-edge research opportunities for experts and scholars in clinical science fields such as oncology, autoimmune diseases, metabolic disorders, and neurodegenerative diseases, thereby promoting the generation and transformation of scientific research achievements.
Tens of Millions Lipid Scholars Funding Program
Lipidomics, as a biomarker, exhibits high disease specificity and stable abundance, providing crucial clues for the prevention, diagnosis, and treatment of diseases.AliveX Biotech Launches the "Lipid Scholar Program" Worth RMB 10 Million,Aimed at funding outstanding researchers to jointly promote the discovery of new mechanisms and biomarkers in the field of clinical medicine through lipidomics.
Application Requirements:
Clinical scientists in China specializing in oncology, autoimmune diseases, metabolic diseases, and neurodegenerative diseases.
The application team needs to provide at least 80 biological samples by September 30, 2024, such as fresh or -80°C frozen serum, plasma, whole blood, cerebrospinal fluid, urine, etc., with priority given to multi-timepoint samples collected before and after medication or at different stages of disease progression.
AliveX Biotech Expert Committee Will Optimize After Evaluation20 unitsResearch Project，Highest Funding Project50% of the total amountThe comprehensive targeted lipidomics Panel testing, standard analysis, personalized analysis, AI analysis, and full-process project guidance services provided by the professor and expert team.
Selected teams can enjoy discounted prices for participating in other omics testing and analysis services.
Target Output: 1. Biomarkers or targets for the target problem; 2. Publication in a Zone 1 journal of the Chinese Academy of Sciences; 3. Potential patent or product commercialization opportunities.
Tens of Millions Immune Digital Twin Model Funding Program
Digital twin technology uses multi-omics patient data, public data, etc. to establish quantitative disease models, simulating disease or drug mechanisms. It empowers the exploration of key mechanisms and targets, evaluation of therapeutic targets, prediction of drug responses, patient stratification, repurposing of existing drugs, and more, showing great potential for scientific research and translational medicine applications. To promote the development of digital twin technology in China's translational medicine,AliveX Biotech Launches "Immune Digital Twin Model Program" Worth Tens of Millions, aiming to fund outstanding researchers in the field of immunology, jointly promoting the development and application of digital twin models for diseases and drugs.
Application Requirements:
Clinical scientists in China specializing in oncology, autoimmune diseases, metabolic diseases, and neurodegenerative diseases.
The application team needs to provide multi-timepoint, multi-omics data for at least 30 cases showing the progression before and after medication or across different stages of the disease (including at least two of the following types of sequencing data: single-cell transcriptomics, flow cytometry, cytokines, metabolomics, lipidomics, transcriptomics) by September 30, 2024. This should also include relevant clinical treatment and drug data.
AliveX Biotech Expert Committee Will Optimize After EvaluationThreeResearch Project，FreeProvideAI Analysis and Digital Twin Mechanism Modeling with Full-Process Guidance Services from Academician Experts.
Selected teams can enjoy discounted prices for other omics testing and analysis services.
Target Output: 1. Biomarkers or targets for the target problem; 2. Publications in top-tier journals in related clinical disease treatment fields; 3. Potential patent and product conversion opportunities.
Registration Method
Method 1:
Scan the QR code above to fill out the funding plan application form. A dedicated customer service representative and sales colleague will contact you to discuss the project and conduct a project evaluation.
Method Two:
Scan the QR code above to add AliveX Biotech's customer service assistant, and obtain the entry link and QR code for the application form of the funding program. A dedicated sales colleague will contact you to discuss and evaluate the project.
The company reserves all rights to interpret this funding program.
About AliveX Biotech
AliveX Biotech is a leading AI + multi-omics technology platform company in China, with an end-to-end dry and wet lab closed-loop multi-omics experimental platform and an AI bio-computing platform. This includes high-quality biological detection and analysis technologies such as spatiotemporal single-cell omics, targeted proteomics, metabolomics/lipidomics, as well as computational technologies like multi-omics integrated analysis, AI modeling, knowledge graphs, and disease pharmacological mechanism modeling to efficiently empower R&D. AliveX Biotech boasts an internationally leading interdisciplinary team of academician professors and industry experts, providing customized scientific research solutions for research institutions and pharmaceutical partners, including studies on disease and drug mechanisms, discovery and evaluation of biomarkers and targets, patient stratification, multimodal AI prediction, optimization of clinical trial protocols, and precision treatment plans. AliveX Biotech has served over a hundred clinical and scientific research institutes and international large pharmaceutical companies. The company owns dozens of core technology independent intellectual property rights and has obtained national high-tech enterprise certification, CAP certification from the American Pathology Society, and ISO9001 certification.
